For Immediate Release

Chicago, IL – October 21, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Biogen Idec (BIIB), Elan (ELN), UnitedHealth Group Inc. (UNH), Forest Laboratories, Inc. (FRX) and Cypress Biosciences (CYPB).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Tuesday’s AnalystBlog:

Biogen Reports Higher Earnings

Today morning, Biogen Idec (BIIB) reported third quarter earnings per share of $1.12, beating the Zacks Consensus Estimate of $1.02. The company reported earnings of 98 cents in the year-ago period. Revenues increased 3% to $1.12 billion, with Tysabri being the primary growth

...

This morning, Forest Laboratories, Inc. (FRX), reported earnings per share of 85 cents for the second quarter of fiscal 2010, in-line with the Zacks Consensus Estimate. Product sales increased 4% to $962.7 million. Although Lexapro sales declined 3.1% to $566 million, Namenda, which is approved for the treatment of moderate and severe Alzheimer’s disease, delivered sales of $275.3 million, recording a growth of 11.9% from the year-ago period. Improved patient access and increased promotional efforts should help keep Namenda sales strong. Bystolic, Forest’s beta-blocker for the treatment of hypertension, posted sales of $40.7 million. This was significantly higher than the year ago sales of $14.2 million. Contract revenue, consisting primarily of Benicar co-promotion income, increased 7.2% to $50.6 million. Forest’s most recent product launch, Savella, which is approved for the management of fibromyalgia, posted sales of $10.2 million. The product, which has been developed in ...

We are pleased to hear that Forest Laboratories (FRX) presented encouraging data from its phase III trial of ceftaroline for the treatment of community-acquired pneumonia (CAP) in hospitalized patients. The company presented new data from two multicenter studies – FOCUS 1 and FOCUS 2 – at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco. In addition to CAP, ceftaroline is also being studied for complicated skin and skin structure infections (cSSSI) caused by gram-positive bacteria.

The randomized, double-blind trial compared ceftaroline with ceftriaxone in hospitalized adult patients with moderate to severe CAP. Following both the trials, it was found that patients treated with ceftaroline demonstrated a better cure rate (84.3%) compared to those treated with ceftriaxone (77.7%). In addition, the overall microbiological response rate in the microbiologically evaluable (ME) population was 87% for ceftaroline and 81% for ceftriaxone, while in the microbiological modified intent-to-treat (MITT)

...

We are presenting a list of companies which we believe are currently mispriced, based on our estimate of fair value, by the market. We develop our fair value ranges by projected free cash flow out one year and estimating an appropriate FCF multiple based on our assessment of risk and the strength of the balance sheet.

Cisco Systems [CSCO: 19.57, +0.84 (+4.48%)] Recent Price $17.04 Value Range 21.86 – $38.41 Cisco Systems, Inc. designs, manufactures and sells Internet protocol (IP)-based networking and other products related to the communications and information technology (IT) industry, and provides services associated with these products and their use. The Company provides a line of products for transporting data, voice, and video within buildings, across campuses, and around the world. Its products are designed to transform how people connect, communicate and collaborate. Cisco Systems, Inc.’s products, which include primarily routers, switches, and products that the

...

For Immediate Release

Chicago, IL - June 29, 2009 - Zacks Equity Research highlights Strayer Education (STRA) as the Bull of the Day and Red Robin Gourmet Burgers (RRGB) the Bear of the Day. In addition, Zacks Equity Research provides analysis on Forest Laboratories, Inc. (FRX), ViroPharma (VPHM) and Pfizer (PFE).

Full analysis of all these stocks is available at http://at.zacks.com/?id=2676.

Here is a synopsis of all five stocks:

Bull of the Day:

Financial results for the past thirteen quarters at Strayer Education (STRA) have been above expectations, and management's guidance for 2009 portends continued double-digit EPS growth.

The company benefits from positive pricing through annual 5% tuition increases with the 2009 tuition increase having been announced concurrent with the third quarter earnings report.

Despite the stock's valuation being in

...

For Immediate Release

Chicago, IL - June 18, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Apple (AAPL), Integrated Device Technology (IDTI), Leadis Technology (LDIS), Forest Laboratories, Inc. (FRX) and FedEx Corporation (FDX).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Wednesday's Analyst Blog:

Touch-Screens Feeling Hot

This technology seemed to struggle to gain acceptance until Apple (AAPL) released the iPhone.

The capacitive touch-screen and touch-button controller segment is projected to hit 1.3 billion units by 2012, a 44 percent compounded annual growth rate, according to

...

For Immediate Release

Chicago, IL - May 14, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Cypress Bioscience, Inc. (CYPB), Forest Laboratories, Inc. (FRX), Allied Irish Banks, p.l.c. (AIB), Baxter International (BAX) and Pfizer (PFE).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579.

Here are highlights from Wednesday's Analyst Blog:

Cypress Bio Banks on Savella

Cypress Bioscience, Inc. (CYPB) reported financial results for the first quarter 2009 on May 11, 2009. Total revenues for the quarter were $7.9 million, and consisted primarily of collaborative payments from Savella development partner, Forest Laboratories,

...

Cypress Bioscience, Inc. (CYPB) reported financial results for the first quarter 2009 on May 11, 2009. Total revenues for the quarter were $7.9 million, and consisted primarily of collaborative payments from Savella development partner, Forest Laboratories, Inc. (FRX). This was generally in-line with our $8.2 million forecast.Net loss for the quarter was $9.2 million -- and significantly greater than our expectations -- due to approximately $5.0 million in R&D expense associated with a $3.0 million milestone payment to a licensor, Pierre Fabre, upon NDA approval of Savella and a $2.0 million payment in connection with an asset purchase transaction for a technology to diagnose and monitor Lupus. Earnings per share (EPS) for the first quarter equated to ($0.24). Cypress Bio exited the first quarter with $160.4 million in cash.Savella is now commercially available and priced at roughly $1500/year. We see peak sales potential ...

For Immediate Release

Chicago, IL - April 23, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: UTX Corp. (UTX), Comerica Inc. (CMA), Brinker International (EAT), Regions Financial Corp. (RF) and Forest Laboratories, Inc. (FRX).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579.

Here are highlights from Wednesday's Analyst Blog:

UTX Revenues Down 12+%

UTX Corp. (UTX) released Q1-09 results today. Revenues of $12.2 billion were down 12.2% from $14.0 billion last year (which, in turn, was adjusted upward by $257 million at Pratt & Whitney) for collaborative arrangements per EITF Issue

...

Forest Labs' Fiscal Fourth Quarter and Full-Year Financial ResultsThis morning, Forest Laboratories, Inc. (FRX) reported financial results for the period ending March 31, 2009. Revenue for the fiscal fourth quarter 2009 came in $965.5 million, down 3% from the same period in 2008 and 4% lower than our estimate of $1,005 million.Sales were below our forecast due to lower-than-anticipated sales of Lexapro which ended the quarter at $549 million, down 5% from the fourth quarter 2008 and below our $585 million forecast. Sales for the fiscal year ending March 31, 2009 came in at $3,923 million, up 2% from 2008.EPS was $0.31 in the most recent quarter which included a $170 million ($0.45 per share) pretax charge for reserves related to an investigation into Forest's marketing of Lexapro, Celexa and Levothroid. Excluding this charge and EPS was $0.76 down from $0.91 posted ...